title: High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know.
abstract: Neuropathic pain is a frequent and disabling condition with diverse underlying etiologies and is often difficult to treat. Systemic drug treatment is often limited in efficacy. Furthermore, adverse effects may be a limiting factor when trying to reach the necessary dose. Analgesics that can be applied topically have the potential to largely overcome this problem. They may be of particular advantage in localized neuropathic pain syndromes such as postherpetic neuralgia or small fiber neuropathy. Capsaicin, the pungent component of chili peppers, is a natural ligand of the transient receptor potential vanilloid 1 channel and has long been used as topically applicable cream with concentrations of 0.025 to 0.075%. In 2009, a high-concentration transdermal capsaicin 8% patch (Qutenza(®); Acorda Therapeutics, Inc., Ardsley, NY, USA; Astellas Pharma Europe Ltd., Chertsey, Surrey, UK) was introduced for the treatment of peripheral neuropathic pain syndromes other than of diabetic origin in adults. It has since been widely used in diverse neuropathic pain disorders. In this review article, we summarize current knowledge on Qutenza, its advantages and problems, and expose unmet needs.
authors: Department of Neurology, University of Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg, Germany.
authors: Nurcan
authors: N
authors: Üçeyler
authors: Department of Neurology, University of Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg, Germany. sommer@uni-wuerzburg.de.
authors: Claudia
authors: C
authors: Sommer
keywords: Analgesia; Capsaicin; Neuropathic pain; Qutenza; Transient receptor potential vanilloid 1 (TRPV1)